Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib) in MDM2-amplified cancers ongoing and ahead of schedule. Interim.

WATERTOWN, Mass., Sept. 24, 2019 -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients,.

Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the presentation of interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification at the 2019 Congress of the European Society for Medical Oncology (ESMO) (Presentation Number: 475P). The reported safety results show that the combination has been very well-tolerated in the trial, with the most common non-hematological related adverse events grade ≤2 being nausea (46%) and fatigue (23%).

ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of a variety of cancers, including cancers with MDM2-amplified tumors. For information about Aileron’s clinical trials, please visit www.clinicaltrials.gov. Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, including statements about Aileron’s clinical trials, financial prospects, future operations and sufficiency of funds for future operations, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019. The dose-optimization Phase 1b portion of the Phase 1b/2 clinical trial started dosing small cell lung cancer (SCLC) patients in September 2019.

Aileron Therapeutics (ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer (SCLC) against chemotherapy-induced toxicity, a concept known as chemoprotection (or myelopreservation). The Company expects to enroll approximately 8 patients into this dose optimization expansion cohort to further evaluate the selected dose for chemoprotection from topotecan-induced bone marrow toxicities.

Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. Management plans to expand its ongoing clinical myelopreservation trial to include two additional cohorts: an expansion cohort in small-cell lung cancer patients and a cohort in non-small-cell lung cancer patients. Company expects to present key findings of the phase 1b portion of this myelopreservation trial in the 2nd quarter of 2020.

The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence ...

Aileron Therapeutics (ALRN) today announced plans to report interim results from their Phase 1b/2 clinical trial of ALRN-6924 in small cell lung cancer (SCLC). In this trial, ALRN-6924 is being evaluated as an agent to protect cancer patients against chemotherapy-induced toxicity, a concept known as myelopreservation or chemoprotection.

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy..

ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of a variety of cancers, including cancers with MDM2-amplified tumors. For information about Aileron’s clinical trials, please visit www.clinicaltrials.gov.

Aileron Therapeutics (ALRN) today reported business highlights and financial results for the first quarter ended March 31, 2020. “We look forward to announcing interim data from the dose optimization part of the study in the 2nd quarter of this year.”

Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, presented new data at the 2019 AACR-NCI-EORTC Conference from nonclinical studies in which ALRN-6924, a dual inhibitor of MDM2 and MDMX, prevented chemotherapy-related toxicities in cellular studies and mouse models of cancer without limiting – and even enhancing – anti-cancer efficacy. “Chemotherapy is widely used to treat – and often cure – millions of cancer patients each year, but chemotherapy is toxic and commonly causes severe or life-threatening side effects,” said Dr. Manuel Aivado, President and CEO of Aileron Therapeutics.

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

As the US$26m market cap Aileron Therapeutics, Inc. (NASDAQ:ALRN) released another year of negative earnings...

WATERTOWN, Mass., Oct. 31, 2019 -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the.

Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of.

Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer, effective immediately. Mr. Wanstall has served as the Company’s Vice President of Finance and Operations and principal accounting officer since 2018. The first is studying ALRN-6924 as a myelopreservation agent to protect cancer patients against chemotherapy-induced toxicities that is currently in a Phase 1b/2 clinical study, with data expected to be reported in the second quarter of 2020.

Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Don Dougherty, its current Chief Financial Officer, will be leaving Aileron effective September 13, 2019. All financial responsibilities are being transitioned to Richard Wanstall, who has served as the Company’s Vice President of Finance and Operations and principal accounting officer since 2018. “During this past year, we have built a strong leadership team with the hiring of Vojislav (Vojo) Vukovic, MD, PhD as Chief Medical Officer, Kathryn Gregory, MBA as Chief Business Officer, and the promotion of Allen Annis, PhD, as Senior Vice President of Research.